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grade 2 or greater were 6.8% and 8.1%; and for gastrointestinal toxicities were 2.7% and 2%. We have found only a statistically
signiﬁcant difference in univariate analysis in rate of DFS with Swift (1.7%) vs tomography (7%).
Conclusions. In patients with PC, the treatment with EBRT and boost with HDR-BT allows deliver high BED with excellent results
and minimal toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.809
Cross-sectional observational study about prevalence of metabolic syndrome in prostate cancer treated with
androgen deprivation therapy (SIMBOSPROST). Group GICOR
J. Mun˜oz García1, P. Samper Ots2, Y. Ríos Kavadoy1, M. Couselo Paniagua3, E. Villafranca Iturre4,
M. Rodríguez Lin˜án5, A. Pérez Casas6, R. Muelas Soria7, B. Luden˜a Martínez8, J. López Torrecilla9, A. Zapatero10,
M. Márquez García11
1 Hospital Infanta Cristina, Oncología Radioterápica, Spain
2 Hospital Rey Juan Carlos, Oncología Radioterápica, Spain
3 Hospital Militar Central Gomez Ulla, Oncología Radioterápica, Spain
4 Hospital de Navarra, Oncología Radioterápica, Spain
5 Complejo Hospitalario Reina Sofía, Oncología Radioterápica, Spain
6 Fundación Jiménez Díaz, Clínica NTRA, Sra. de la Concepción, Oncología Radioterápica, Spain
7 Hospital Provincial de Castellon, Oncología Radioterápica, Spain
8 Hospital Fuenlabrada, Oncología Radioterápica, Madrid, Spain
9 Hospital General Universitario, Oncología Radioterápica, Spain
10 Hospital La Princesa, Oncología Radioterápica, Madrid, Spain
11 Hospital General Juan Ramón Jimenez, Oncología Radioterápica, Spain
Objective. The International Diabetes Federation (IDF) estimated that around 20–25% of the adult population of the world has
metabolic syndrome (MetS). The patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT), have
been reported to have higher prevalence of MetS. The objective of the study was to assess, the prevalence of MetS in patients
with PC who have received or will receive radiation therapy (RT) with radical intention and ADT.
Materials and methods. Multicenter prospective observational cross-sectional study of patients with PC who have received or will
receive RT with radical intention and ADT (6, 12–18, ≥24 months, and a control group without ADT), with the main primary
objective to analyze the prevalence of MetS in these pts. The presence of MetS was deﬁned according to the updated National
Cholesterol Education Program’s Adult Treatment Panel III by the presence of 3 or more of the following risk factors: (1) waist
circumference≥102 cm (European Cardiovascular Societies), (2) fasting blood sugar≥100mg/dL or previously diagnosed type
2 diabetes, (3) serum triglyceride level≥150mg/dL or pharmacological treatment for it, (4) systolic blood pressure≥130mm
Hg or diastolic blood pressure≥85mm Hg or previously diagnosed hypertension, and (5) high-density lipoprotein (cHDL) choles-
terol < 40 mg/dL. The study was approved by the Clinical Research Ethics Committee and the patient signed the informed consent
form.
Results. From November 2011 to October 2012, 256 pts were included in the study (50 pts without ADT, 55 pts with 6 months of
hormonal therapy, 91 pts in the group of 12–18 months and 60 pts in the group of ≥24 months ADT), and according to the above
criteria, 118 pts (46%) had MetS and are the object of our study. Median age was 72 years old (range 56-86). The prevalence of
MetS was 19.5% in patients without ADT, 20.3% in patients that received ADT for 6 months, 35.6% in pts treated for 12–18 months
with ADT and 24.6% in pts that received >24 months of hormonal therapy. The majority of pts had no family history of diabetes
mellitus, hypertension or dislipidemia.
Conclusion. According to our results patients with prostate cancer treated with androgen deprivation therapy for 12–18 months
present a higher prevalence of metabolic syndrome than patients treated with shorter or longer periods of hormonal treatment
and the general population.
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Purpose/objectives. Ki67 is a proliferation marker that provides an accurate estimate of growth fraction and outcome for patients
with prostate cancer. Expression of ERG (androgen dependent due to TMPRSS2-ERG fusion), are present in more than 50% of
